Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
Clinical trial NCT03588299 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03588299
- Sponsor
- Bayer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-07
- Primary completion
- 2026-09-15
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.